CSF2 and neoplasm: Collectively, the results from preclinical models suggest that the combination of GM-CSF and GALV-GP-R− transgenes in an OI offers a greater ability to directly kill tumors and induce systemic anti-tumor immune responses compared with GM-CSF alone; however, head-to-head comparisons in clinical trials have not been performed.